<DOC>
	<DOCNO>NCT00664833</DOCNO>
	<brief_summary>This multicentre , cluster-randomized , open-label flexible dose study 2x2 factorial design administration vardenafil dose 5 , 10 20 mg dos male erectile dysfunction.The treatment period 12 week , 4 week unmedicated period subject take ED medication . For ED treatment-na√Øve subject ( ie , previously treat ED medication ) , unmedicated period 2 weeks.Approximately 150 investigational centre may utilise approximately 10 subject screen enter 4 week treatment free period Visit 1 subsequently enroll approximately 1380 subject therapy . Each centre enroll 10 subject . Sites try recruit approximately 50 % subject previously try oral PDE5 inhibitor therapy erectile dysfunction . An attempt make enroll subject whose partner interested involved.Sites randomize 1:1:1:1 ratio receive either education intervention Primary care Physician ( PCP ) level , subject level , level intervention ( usual care ) . The PCP education program accredit CME program include comprehensive overview screen diagnosis ED , available treatment option appropriate treatment selection , well subject partner counseling . The subject education two-pronged approach include physician-to-subject instruction direct-to-subject education method . After unmedicated period , treatment initiate vardenafil 10 mg tablet 4 week . This follow flexible dose titration period 4 week subject may maintain previous dosage regimen step 20 mg vardenafil step 5 mg vardenafil . There final 4 week treatment period previous dosage regimen either maintain , increase decreased one step accord three applicable dosage strength vardenafil ( 5 , 10 20 mg ) . The high applicable dosage regimen 20 mg vardenafil exceed . A 24 hour follow-up phone call require within 24 hour last dose vardenafil collect data concern serious adverse event , need .</brief_summary>
	<brief_title>Evaluation LEVITRA Advance Treatment Erectile Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Males erectile dysfunction six month accord NIH Consensus Statement ( inability attain and/or maintain penile erection sufficient satisfactory sexual performance ) . Heterosexual relationship The subject must make least four attempt sexual intercourse ( accord question subject diary : `` Was sexual activity initiate intention intercourse ? '' ) four separate day untreated baseline period . At least 50 % attempts period must unsuccessful , accord follow question subject diary [ least one question answer `` No '' ] : `` Were able achieve least erection ( enlargement penis ) ? `` , `` Were able insert penis partner 's vagina ? '' `` Did erection last long enough successful intercourse ? '' Previous Current Medical Conditions : Any unstable medical , psychiatric substance abuse disorder , opinion Investigator , likely affect subject 's ability complete study precludes subject 's participation study . Presence penile anatomical abnormality ( eg . penile fibrosis Peyronie 's disease ) opinion Investigator would significantly impair sexual performance . History surgical prostatectomy ( transurethral intervention exclude ) . Hereditary degenerative retinal disorder retinitis pigmentosa . Any underlying cardiovascular condition include unstable angina pectoris , would preclude sexual activity . Patients 65 year old start dose 10 mg judge investigator unsuitable . Uncontrolled atrial fibrillation/flutter screening ( ventricular response rate &gt; 100 bpm ) . Severe chronic acute liver disease , history moderate severe hepatic impairment . Resting hypotension ( rest systolic blood pressure &lt; 90 mm Hg ) hypertension ( rest systolic blood pressure &gt; 170 mm Hg rest diastolic blood pressure &gt; 110 mm Hg ) . Symptomatic postural hypotension within six month Visit 1 . NYHA Class III IV heart failure Concomitant Medications : Subjects take nitrate nitric oxide donor . Subjects take anticoagulant , except antiplatelet agent . Subjects take androgen . Subjects take follow inhibitor cytochrome P 450 CYP 3A4 : potent HIV protease inhibitor ( ritonavir , indinavir ) , antimycotic agent itraconazole ketoconazole ( topical form allow ) erythromycin . Subjects received investigational drug ( include placebo ) within 30 day Visit 1 . Use treatment erectile dysfunction within 7 day Visit 1 study , include oral medication , vacuum device , constrictive device , injection urethral suppository . Known hypersensitivity Vardenafil , Bay 389456 component investigational medication . Patients history unresponsiveness PDE V inhibitor treatment due lack efficacy significant side effect lead discontinuation PDE V inhibitor . Subjects take alpha blocker . Other Exclusions : Subjects unwilling cease use vacuum device , intracavernosal injection , Viagra therapy erectile dysfunction . Subjects unwilling unable complete subject diary . Subjects illiterate unable understand questionnaire subject diary . Subjects unwilling refrain consume grapefruit juice product contain grapefruit juice study medication .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Erectile dysfunction</keyword>
	<keyword>Phosphodiesterase Type 5 Inhibitors</keyword>
	<keyword>Patient education</keyword>
	<keyword>Impotence</keyword>
	<keyword>Vardenafil</keyword>
</DOC>